Zacks Investment Research downgraded shares of Abiomed, Inc. (ABMD) from OUTPERFORM to NEUTRAL on July 10, 2012, with a target price of $25.00.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Abiomed, Inc. (ABMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment